The pharmacokinetics and bioavailability of a new chemosensitizer, SDZ PSC 833, in patients with advanced cancer

Thiessen, Jake J.; Erlichman, Charles; Moore, Malcolm J.; DeAngelis, Carlo; Goodman, Phyllis J.; Manzo, J

doi:10.1097/00001813-199409001-00101

Search citation statements

Order By: Relevance

Paper Sections

Select...

Pharmacokinetic Analyses1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2000

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The valspodar concentration in whole blood was determined using a radioimmunoassay (RIA) as previously published. 67 Samples for measurement of plasma concentrations of DNR and the hydroxylated metabolite DNR-ol were taken on day 3 of cycle 1, just before, just after, and at 4, 24, and 48 h after DNR administration. Blood samples (5 ml) were drawn into heparinized tubes and centrifuged as soon as possible, and the plasma was immediately transferred into uncoated polypropylene tubes and deep frozen at 7208C.…”

Section: Pharmacokinetic Analysesmentioning

confidence: 99%

Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia

Sonneveld¹,

Burnett²,

Vossebeld³

et al. 2000

Hematol J

View full text Add to dashboard Cite

show abstract

Section: Pharmacokinetic Analysesmentioning

confidence: 99%

Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia

Sonneveld¹,

Burnett²,

Vossebeld³

et al. 2000

Hematol J

View full text Add to dashboard Cite

show abstract

Phase I Dose-Finding and Pharmacokinetic Study of Paclitaxel and Carboplatin With Oral Valspodar in Patients With Advanced Solid Tumors

Patnaik

Michael

Egorin

et al. 2000

JCO

View full text Add to dashboard Cite

The recommended phase II dose in chemotherapy-naïve patients is paclitaxel 81 mg/m(2), carboplatin AUC 6 mg.min/mL, and valspodar 5 mg/kg every 6 hours. In previously treated patients, the recommended phase II dose is paclitaxel 67.5 mg/m(2), carboplatin AUC 6 mg.min/mL, and valspodar 5 mg/kg every 6 hours. The acceptable toxicity profile supports the rationale for performing disease-directed evaluations of paclitaxel, carboplatin and valspodar on the schedule evaluated in this study.

show abstract

P-Glycoprotein Inhibitor Valspodar (PSC 833) Increases the Intracellular Concentrations of Daunorubicin In Vivo in Patients With P-Glycoprotein–Positive Acute Myeloid Leukemia

Tidefelt

Liliemark

Gruber

et al. 2000

JCO

View full text Add to dashboard Cite

show abstract

The pharmacokinetics and bioavailability of a new chemosensitizer, SDZ PSC 833, in patients with advanced cancer

Cited by 3 publications

References 0 publications

Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia

Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia

Phase I Dose-Finding and Pharmacokinetic Study of Paclitaxel and Carboplatin With Oral Valspodar in Patients With Advanced Solid Tumors

P-Glycoprotein Inhibitor Valspodar (PSC 833) Increases the Intracellular Concentrations of Daunorubicin In Vivo in Patients With P-Glycoprotein–Positive Acute Myeloid Leukemia

Contact Info

Product

Resources

About